Shant Biotech SA
Shant Biotech reported total assets of €11.0m at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Shant Biotech shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +75 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Shant Biotech's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 26 Aug 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Shant Biotech's financial analysis
- Solvency94.4%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Shant Biotech
Shant Biotech's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0680.795.389
- VAT number
- BE0680795389
- Peppol
- Registered · 0208:0680795389 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 07 Sep 2017
- Registered office
- 1480 Tubize
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Shant Biotech (SA) has been based in Tubize since 2017, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 201,509 € and equity of €10.4m; its revenue is not published. Its solvency stands at 94.4%, above the median of its sector (38.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Shant Biotech
Companies in the same business, of comparable size and area, outside its group.
- Phoenix Biosciences Manufacture of pharmaceutical preparations Nivelles · balance sheet €8.11m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- White Raven Manufacture of pharmaceutical preparations Liège · balance sheet €9.55m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- CellCarta Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €22.4m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
Frequently asked questions about Shant Biotech
What is the revenue of Shant Biotech?
Shant Biotech files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Shant Biotech?
In Belgium, the VAT number is the company number prefixed with BE: BE0680795389 for Shant Biotech, if the company is VAT-registered. Its company number (CBE) is 0680.795.389.
Where is the registered office of Shant Biotech?
According to the CBE register, the registered office of Shant Biotech is in 1480 Tubize.
What is the equity of Shant Biotech?
At the close of the 2025 financial year, the equity of Shant Biotech amounts to 10,423,060 €, a solvency of 94.4% of total assets.
Who manages Shant Biotech?
The register lists 2 active mandates at Shant Biotech. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Shant Biotech
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →